The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.
Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy
Open accessAbstract
Importance: Preservation of peripheral visual field (VF) is considered an advantage for anti-vascular endothelial growth factor agents compared with panretinal photocoagulation (PRP) for treatment of proliferative diabetic retinopathy. Long-term data on VF are important when considering either treatment approach. Objective: To further evaluate changes in VF throughout 5 years among eyes enrolled in the Protocol S clinical trial, conducted by the DRCR Retina Network. Design, Setting, and Participants: Post hoc analyses of an ancillary study within a multicenter (55 US sites) randomized clinical trial. Individuals with eyes with proliferative diabetic retinopathy enrolled in Protocol S were included. Data were collected from February 2012 to February 2018. Analysis began in June 2018. Interventions: Panretinal photocoagulation or intravitreous injections of 0.5-mg ranibizumab. Diabetic macular edema, whenever present, was treated with ranibizumab in both groups. Panretinal photocoagulation could be administered to eyes in the ranibizumab group when failure or futility criteria were met. Main Outcomes and Measures: Mean change in total point score on VF testing with the Humphrey Field Analyzer 30-2 and 60-4 test patterns. Results: Of 394 eyes enrolled in Protocol S, 234 (59.4%) were targeted for this ancillary study. Of these, 167 (71.4%) had VF meeting acceptable quality criteria at baseline (median [interquartile range] age, 50 [43-58] years; 90 men [53.9%]). At 5 years, 79 (33.8%) had results available. The mean (SD) change in total point score in the PRP and ranibizumab groups was -305 (521) dB and -36 (486) dB at 1 year, respectively, increasing to -527 (635) dB and -330 (645) dB at 5 years, respectively (P = .04). After censoring VF results after PRP treatments in the ranibizumab group, the 5-year mean change in total point score was -201 (442) dB. In a longitudinal regression analysis of change in total point score including both treatment groups, laser treatment was associated with a mean point decrease of 208 (95% CI, 112-304) dB for the initial PRP session, 77 (95% CI, 21-132) dB for additional PRP sessions, and 325 (95% CI, 211-439) dB for endolaser. No association was found between change in point score and the number of ranibizumab injections during the previous year (-9 per injection [95% CI, -22 to 3]). Conclusions and Relevance: The limited data available from Protocol S suggest that there are factors besides PRP associated with VF loss in eyes treated for proliferative diabetic retinopathy. Further clinical research is warranted to clarify the finding. Trial Registration: ClinicalTrials.gov identifier: NCT01489189.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ACE inhibitors, ARBs, and fibrates may have specific benefit in diabetic retinopathy.
“In addition, pharmacologic treatment approaches may have specific benefit in diabetic retinopathy, including ACE inhibitors, ARBs,529,530 and fibrate lipid-lowering agents.531–533”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [532]
The Abstract and Conclusions (page unavailable) address panretinal photocoagulation and ranibizumab, not ACE inhibitors, ARBs, or fibrates. Searches for those drug classes and for fenofibrate found no passage in our copy addressing their benefit in diabetic retinopathy. (LLM, conf=0.76)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,822
Barber, A. J., Lieth, E., Khin, S. A., Antonetti, D. A., Buchanan, A. G., & Gardner, T. W. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2425 · Cited by 1,298
Self-citationPanretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy
Gross, J. G., Glassman, A. R., Jampol, L. M., Inusah, S., Aiello, L. P., Antoszyk, A. N., Baker, C. W., Berger, B. B., Bressler, N. M., Browning, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.15217 · Cited by 801
Self-citationGross, J. G., Glassman, A. R., Liu, D., Sun, J. K., Antoszyk, A. N., Baker, C. W., Bressler, N. M., Elman, M. J., Ferris, F. L., Gardner, T. W., et al. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3255 · Cited by 404
Self-citationDiabetic retinopathy is a neurodegenerative disorder
Lynch, S. K., & Abràmoff, M. D. (2017) · Vision Research · doi:10.1016/j.visres.2017.03.003 · Cited by 205
Li, Y., Zhang, F., Nagai, N., Tang, Z., Zhang, S., Scotney, P. D., Lennartsson, J., Zhu, C., Qu, Y., Fang, C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33673 · Cited by 196
VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma
Foxton, R. H., Finkelstein, A., Vijay, S., Dahlmann-Noor, A. H., Khaw, P. T., Morgan, J. E., Shima, D. T., & Ng, Y. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.032 · Cited by 193
Diabetic Retinopathy Viewed as a Neurosensory Disorder
Bresnick, G. H. (1986) · Archives of Ophthalmology · doi:10.1001/archopht.1986.01050190047037 · Cited by 153
Bressler, S. B., Edwards, A. R., Chalam, K. V., Bressler, N. M., Glassman, A. R., Jaffe, G. J., Melia, M., Saggau, D. D., & Plous, O. Z. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.1698 · Cited by 105
Self-citationNicholson, L., Crosby‐Nwaobi, R., Vasconcelos, J. C., Prevost, A. T., Ramu, J., Riddell, A., Bainbridge, J. W., Hykin, P. G., & Sivaprasad, S. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-23509 · Cited by 41
Hellgren, K., Agardh, E., & Bengtsson, B. (2014) · Diabetes · doi:10.2337/db13-1628 · Cited by 33
Total deviation probability plots for stimulus size v perimetry: a comparison with size III stimuli.
Wall, M., Brito, C. F., Woodward, K. R., Doyle, C. K., Kardon, R. H., & Johnson, C. A. (2008) · PubMed · doi:10.1001/archopht.126.4.473 · Cited by 30
Self-citation
Flagged first, then by citations
1 of the 14 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationVEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
Arrigo, A., Aragona, E., & Bandello, F. M. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2064541 · Cited by 211
Bjornstad, P., Dart, A. B., Donaghue, K. C., Dost, A., Feldman, E. L., Tan, G. S. W., Wadwa, R. P., Zabeen, B., & Marcovecchio, M. L. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13444 · Cited by 167
Antoszyk, A. N., Glassman, A. R., Beaulieu, W. T., Jampol, L. M., Jhaveri, C. D., Punjabi, O. S., Salehi-Had, H., Wells, J. A., Maguire, M. G., Stockdale, C. R., et al. (2020) · JAMA · doi:10.1001/jama.2020.23027 · Cited by 132
Self-citationDiabetic Retinopathy Preferred Practice Pattern®
Lim, J. I., Kim, S. J., Bailey, S. T., Kovach, J. L., Vemulakonda, G. A., Ying, G., & Flaxel, C. J. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.12.020 · Cited by 131
Bahr, T. A., & Bakri, S. J. (2023) · Life · doi:10.3390/life13051098 · Cited by 91
Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy
Crabtree, G. S., & Chang, J. S. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01396-2 · Cited by 54
It is time for a moonshot to find “Cures” for diabetic retinal disease
Levine, S. R., Sapieha, P. S., Dutta, S., Sun, J. K., & Gardner, T. W. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101051 · Cited by 53
Self-citationA critical review: Psychophysical assessments of diabetic retinopathy
Chen, X. D., & Gardner, T. W. (2020) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2020.08.003 · Cited by 49
Self-citationFallico, M., Maugeri, A., Lotery, A. J., Longo, A., Bonfiglio, V. M. E., Russo, A., Avitabile, T., Pulvirenti, A., Furino, C., Cennamo, G., et al. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14681 · Cited by 44
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Martínez‐Zapata, M. J., del Salvador, I. C., Martí-Carvajal, A. J., Pijoán, J. I., Cordero, J., Ponomarev, D., Kernohan, A., Solà, I., & Virgili, G. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008721.pub3 · Cited by 39
Glassman, A. R., Elmasry, M. A., Baskin, D. E., Brigell, M., Chong, V. N., Davis, C. Q., Lesmes, L., Levin, L. A., Maddess, T., Taylor, L. J., et al. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100519 · Cited by 44
Self-citationWidefield Optical Coherence Tomography Angiography in Diabetic Retinopathy
Amato, A., Nadin, F., Borghesan, F., Cicinelli, M. V., Chatziralli, I., Sadiq, S. A., Mirza, R. G., & Bandello, F. M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8855709 · Cited by 35
Sadikan, M. Z., Nasir, N. A. A., Iezhitsa, I. N., & Agarwal, R. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113533 · Cited by 32
Glassman, A. R., Beaulieu, W. T., Maguire, M. G., Antoszyk, A. N., Chow, C. C., Elman, M. J., Jampol, L. M., Salehi-Had, H., Sun, J. K., & DRCR Retina Network (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.1110 · Cited by 26
Self-citationRussell, J. F., Zhou, H., Shi, Y., Shen, M., Gregori, G., Feuer, W. J., Wang, R. K., & Rosenfeld, P. J. (2021) · Retina · doi:10.1097/iae.0000000000003375 · Cited by 19
Integrative Biology of Diabetic Retinal Disease: Lessons from Diabetic Kidney Disease
Pan, W. W., Gardner, T. W., & Harder, J. L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10061254 · Cited by 14
Self-citationProgression to Pars Plana Vitrectomy in Patients With Proliferative Diabetic Retinopathy
Alsoudi, A. F., Wai, K. M., Koo, E. B., Parikh, R., Mruthyunjaya, P., & Rahimy, E. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.1844 · Cited by 13
Zhang, W., Zhao, G., Fan, W., & Zhao, T. (2021) · BMC Ophthalmology · doi:10.1186/s12886-021-01920-8 · Cited by 12
Levine, S. R., Myers, M. G., Barunas, R., Chang, D. S.-T., Dutta, S., Maddess, T., Liebmann, J. M., Sherman, S., Eydelman, M., Sun, J. K., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.33 · Cited by 10
Self-citationNonproliferative and Proliferative Diabetic Retinopathy
Sun, J. K., & Aiello, L. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_24 · Cited by 11
Self-citationLee, H., Cho, S., Park, J., Jin, Y., Kim, H., & Jee, D. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-10280-6 · Cited by 8
Sadikan, M. Z., Nasir, N. A. A., Iezhitsa, I. N., & Agarwal, R. (2021) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v4i3.74 · Cited by 8
Pandya, M., Banait, S., & Daigavane, S. V. (2024) · Cureus · doi:10.7759/cureus.54273 · Cited by 9
Visual Field Changes in Diabetic Retinopathy
Lee, D. H., Vitale, S., Agrón, E., Keenan, T. D. L., Cukras, C. A., & Chew, E. Y. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.04.021 · Cited by 6
Predicting 60–4 visual field tests using 3D facial reconstruction
Dogahe, S. J., Garmany, A., Mousavi, S. S., & Khanna, C. L. (2022) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-321651 · Cited by 6
Lam, R. F., Radke, N. V., Bandello, F. M., Bhende, P., Chen, Y., Cheung, C. M. G., Chhablani, J., Fung, A. T.-C., Hsieh, Y., Lai, C., et al. (2025) · Asia-Pacific Journal of Ophthalmology · doi:10.1016/j.apjo.2025.100262 · Cited by 4
Current Treatment Options for Diabetic Retinal Disease
Bloomquist, R. F., Bloomquist, D. T., & Gardner, T. W. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0548 · Cited by 4
Self-citationSanatkar, M., & Bazvand, F. (2022) · Scientific Reports · doi:10.1038/s41598-022-14745-2 · Cited by 3
Kasetty, V. M., Starnes, D. C., Sood, N., Qin, L. G., Moses, M. M., Frazier, H., Singh, H., & Marcus, D. M. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20221216-02 · Cited by 3
Development and Novel Therapeutics in Diabetic Retinopathy
Ingle, P. V., Hamden, N. A., Soh, W. K., Loh, R. W. H. C., & Hatware, K. V. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998324556240910061514 · Cited by 2
Moore, F. C., Phillips, S., Rubenstein, D., Cullinan, C., Young, C., Feola, A., Ou, X., Cui, X., Patel, R., Rhee, M. K., et al. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.9.5 · Cited by 2
Head Turn During Visual Field Testing to Minimize the Influence of Prominent Facial Anatomy
Mousavi, S. S., Dogahe, S. J., Lyons, L. J., & Khanna, C. L. (2023) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002019 · Cited by 2
Liang, P., Ness, J. N., Rapp, J., Boneva, S., Schwämmle, M. E., Jung, M., Schlunck, G., Agostini, H. T., & Bucher, F. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03223-3 · Cited by 2
Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome
Leung, V., Wong, J., & Grigg, J. (2024) · Documenta Ophthalmologica · doi:10.1007/s10633-024-09999-2 · Cited by 2
Luo, Y., Yin, J., Fang, R., Liu, J., Wang, L., Zhang, H., Zhang, M., Lei, Z., Liang, S., Cui, W., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174574 · Cited by 2
Practicality of Prophylactic Aflibercept to Reduce Diabetic Retinopathy Progression
Apte, R. S., & Hwang, C. K. (2021) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2021.0624 · Cited by 2
Zhao, H.-J., Li, X., Zhao, X., Zhang, Q., He, W., Wei, Y., & Tang, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/1285372 · Cited by 2
RetractedNonproliferative and Proliferative Diabetic Retinopathy
Sun, J. K., & Aiello, L. P. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_24-1 · Cited by 2
Self-citationLi, L., Zhou, Q., & Huang, J. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/2933663 · Cited by 1
Analysis of Standard Automated Visual Field Tests in Glaucoma and the Role of Facial Contour
Sepideh Jamali, D., Garmany, A., Kaplan, T. M., Mousavi, M. S., Ashourizadeh, H., Tarakji, Z., & Khanna, C. L. (2025) · Journal of Glaucoma · doi:10.1097/ijg.0000000000002599 · Cited by 1
High-Risk Diabetic Maculopathy: Features and Management
Pandova, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99748
Rapisarda, L. M., & Barbera, G. (1967) · PubMed
Rodrigues, L. T. D. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2021.tde-11042022-132330
Long term outcomes following anti-VEGF therapy for diabetic macular edema
Maatouk, C. M., Sastry, R., & Singh, R. P. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2131539
Clinical Diagnosis of Neovascular Glaucoma in the Ophthalmology Office
Aboobakar, I. F., & Lin, M. M. (2022) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-031-11720-6_4
Gestion médicochirurgicale de l’hémorragie intravitréenne chez le patient diabétique
Bouazza, M., Razzak, A., Amri, G., Zadnass, M., Rachid, R., & Oubaaz, A. (2023) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2023.02.022
Kasetty, V. M., & Marcus, D. M. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230827-01
Diabetic retinopathy: New insights
Tan, T., Tan, G. S. W., Sadda, S. R., Chakravarthy, U., Sun, J. K., & Wong, T. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00018-x
Self-citationAuthor's Response: Ultrawide field angiography in proliferative diabetic retinopathy
Nidhi, V., Verma, S. M., Shaikh, N. F., Azad, S. V., Chawla, R., Venkatesh, P., Vohra, R., & Кумар, В. (2024) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1058_24
Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy
Perais, J. A., Wright, D. M., Lim, A. L. S., Mohite, A., Reid, G. A., Hillis, P., Sheeran, C., & Lois, N. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.3980
Liang, P., Ness, J. N., Rapp, J., Boneva, S., Schwämmle, M. E., Jung, M., Schlunck, G., Agostini, H., & Bucher, F. (2024) · Figshare · doi:10.6084/m9.figshare.27058982
Liang, P., Ness, J. N., Rapp, J., Boneva, S., Schwämmle, M. E., Jung, M., Schlunck, G., Agostini, H., & Bucher, F. (2024) · Figshare · doi:10.6084/m9.figshare.27058979
Liang, P., Ness, J. N., Rapp, J., Boneva, S., Schwämmle, M. E., Jung, M., Schlunck, G., Agostini, H., & Bucher, F. (2024) · Figshare · doi:10.6084/m9.figshare.27058973
Liang, P., Ness, J. N., Rapp, J., Boneva, S., Schwämmle, M. E., Jung, M., Schlunck, G., Agostini, H., & Bucher, F. (2024) · Figshare · doi:10.6084/m9.figshare.27058976
Lee, H.-J., Cho, S., Park, J., Jin, Y., Kim, H. M., & Jee, D. (2023) · Figshare · doi:10.6084/m9.figshare.24792351
Venkatesh, R., Prabhu, V., Hande, P., Jayadev, C., Roy, R., Shetty, R., Tebhla, S., Raj, P., Pai, M., Tendulkar, K., et al. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07128-0
Costanzo, E., Rossi, T., & Parravano, M. (2026) · Expert Review of Ophthalmology · doi:10.1080/17469899.2026.2666930
Diabetic retinal disease: A sensory neuropathy
Gardner, T. W., & Malik, R. A. (2026) · Handbook of clinical neurology · doi:10.1016/b978-0-443-22212-2.00001-x
Self-citationLuo, T., Zou, Y., & Gao, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1885710
Gardner, T. W. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00020-2
Self-citation
Metadata
- Authors
- Maguire, M. G., Liu, D., Glassman, A. R., Jampol, L. M., Johnson, C. A., Baker, C. W., Bressler, N. M., Gardner, T. W., Pieramici, D., Stockdale, C. R., Sun, J. K., & for the DRCR Retina Network
- Affiliations
- University of Pennsylvania (US)
- Jaeb Center for Health Research (US)
- Northwestern University (US)
- University of Iowa (US)
- Baptist Health Paducah (US)
- Johns Hopkins University (US)
- University of Michigan (US)
- California Retina Consultants (US)
- Joslin Diabetes Center (US)
- Corresponding author
- Glassman, Adam R.
- ORCID
- Venue
- JAMA Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-03-01
- Volume
- 138
- Issue
- 3
- Pages
- 285
- ISSN
- 2168-6165 (ISSN-L)
- PMC
- PMC7042909
- OpenAlex
- W3004235425
- Cited by
- 61
- References
- 14
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 13 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 4
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Ophthalmology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Syracuse University
- University of Washington
- University of Rochester
- NorthShore University HealthSystem
- Ministry of Education, India
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926, P30DK020572)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- proliferative diabetic retinopathy, panretinal photocoagulation, ranibizumab, anti-VEGF therapy, visual field changes, diabetic macular edema, long-term visual outcomes, Humphrey Field Analyzer, retinal neovascularization
- MeSH terms
- Ranibizumab, Adult, Diabetic Retinopathy, Female, Humans, Light Coagulation, Male, Middle Aged, Time Factors, United States, Visual Fields, Treatment Outcome, Recovery of Function, Angiogenesis Inhibitors, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
